Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLX101-Tx phase 3 study in recurrent glioblastoma
NL-OMON59127Phase 3Recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Mar 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of 4-iodophenylalanine I-131 in glioblastoma (GBM) (4 arms), sponsored by Telix Pharmaceuticals Limited. Primary endpoints: Dose-limiting treatment-emergent adverse events, Safety and tolerability and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
4-iodophenylalanine I-131
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON59127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59127.